PubMed Health⌕ Search

Biomedical subjects

C E Dean

Publications and source records attributed to C E Dean.

At least 19 recordsLinked to original sources

Nonadditive hepatic tumor promoting effects by a mixture of two structurally different polychlorinated biphenyls in female rat livers.

This study evaluates and quantifies the interactive hepatic tumor promoting effects of two PCBs, the Ah receptor agonist PCB 126 (3,3',4,4',5-pentachlorobiphenyl) and the constitutive androstane receptor (CAR) agonist PCB 153 (2,2',4,4',5,5'-hexachlorobiphenyl). Promotion of altered hepatic foci was evaluated utilizing a medium-term 8-week bioassay for promoters of hepatocarcinogenesis. The assay employs placental glutathione-S-transferase positive (GST-P+) liver cell foci as markers of preneoplasia in female Fischer 344 rats treated with the known initiator diethylnitrosamine followed by partial hepatectomy and by gavage exposure to test chemicals. GST-P+ foci were quantified by histomorphometry and were reported as areas and numbers of GST-P+ foci within the area of liver examined. For PCB 126, the doses were 0.1, 1.0, and 10 microg/kg body weight. For PCB 153, the doses were 10, 100, 1000, 5000, and 10,000 microg/kg body weight. Combined PCB 126 and 153 exposures were 0.1 + 10, 1 + 100, 10 + 1000, 10 + 5000, and 10 + 10,000 microg/kg, respectively. Individual PCB treatment resulted in dose dependent increases in liver and adipose concentrations. Hepatic PCB 153 levels were significantly increased (p < 0.01) after combined exposure. Treatment with PCB 126 or PCB 153 alone resulted in a significant (p < 0.01) dose dependent increase in GST-P+ foci area and number compared with controls. Treatment with the mixture of PCB 126 and 153 resulted in antagonistic GST-P+ focus formation (p < 0.001) for both foci area and number. The less than additive effect was present at all 5 PCB 126/PCB 153 dose combinations, including the low doses of PCB 126 and 153 that did not show significant promotional activity alone.

Adipose Tissue↗

Somatotroph recruitment by glucocorticoids involves induction of growth hormone gene expression and secretagogue responsiveness.

Prior research indicates that growth hormone (GH) cell differentiation can be induced prematurely by treatment with glucocorticoids in vitro and in vivo. However, the nature of these responses has not been fully characterized. In this study, the time course of corticosterone induction of GH-secreting cells in cultures of chicken embryonic pituitary cells, responsiveness of differentiated somatotrophs to GH secretagogues, localization of somatotroph precursor cells within the pituitary gland, and the effect of corticosterone on GH gene expression were determined to better define the involvement of glucocorticoids in somatotroph recruitment during development. Anterior pituitary cells from embryonic day 12 chicken embryos were cultured in 10(-9) M corticosterone for 4 to 48 h and were then subjected to reverse haemolytic plaque assays (RHPAs) for GH. Corticosterone treatment for as short as 16 h increased the percentage of GH cells compared with the control. When corticosterone was removed after 48 h and cells were cultured for an additional 3 days in medium alone, the percentage of GH secretors decreased but remained greater than the proportion of somatotrophs among cells that were never treated with corticosterone. To determine if prematurely differentiated somatotrophs were responsive to GH secretagogues, cells were exposed to corticosterone for 48 h and then subjected to GH RHPAs in the presence or absence of GH-releasing hormone (GHRH) or thyrotropin-releasing hormone (TRH). Approximately half of the somatotrophs induced to differentiate with corticosterone subsequently released more GH in response to GHRH and TRH than in their absence. The somatotroph precursor cells were localized within the anterior pituitary by culturing cells from the caudal lobe and cephalic lobe of the anterior pituitary separately. Corticosterone induction of GH cells was substantially greater in cultures derived from the caudal lobe of the anterior pituitary, where somatotroph differentiation normally occurs. GH gene expression was evaluated by ribonuclease protection assay and by in situ hybridization. Corticosterone increased GH mRNA in cultured cells by greater than fourfold. Moreover, corticosterone-induced somatotroph differentiation involved GH gene expression in cells not expressing GH mRNA previously, and the extent of somatotroph differentiation was augmented by treatment with GHRH in combination with corticosterone. We conclude that corticosterone increases the number of GH-secreting cells within 16 h, increases GH gene expression in cells formerly not expressing this gene, confers somatotroph sensitivity to GHRH and TRH, and induces GH production in a precursor population found primarily in the caudal lobe of the anterior pituitary, a site consistent with GH localization in adults. These findings support the hypothesis that glucocorticoids function to induce the final stages in the differentiation of fully functional somatotrophs from cells previously committed to this lineage.

Animals↗

Case study: childhood-onset tardive dyskinesia versus choreoacanthocytosis.

A male adolescent presented with aggression, depressed mood, and severe movement disorder that developed at age 5 after exposure to neuroleptics. Evaluation revealed acanthocytes in his blood, which led to a differential diagnosis of tardive dyskinesia versus choreoacanthocytosis. However, this is unusually young age of onset for these conditions. Differential diagnosis, medication management of the movement disorder, and pathophysiological mechanisms in tardive dyskinesia and choreoacanthocytosis are discussed.

Acanthocytes↗

Severe self-injurious behavior associated with treatment-resistant schizophrenia: treatment with maintenance electroconvulsive therapy.

A 35-year-old man with schizophrenia associated with a 10-year history of repetitive and often severe self-injurious behaviors was treated successfully with maintenance electroconvulsive therapy. Initially his condition did not respond to multiple psychotropic agents (including a year-long trial of clozapine), 27 hospitalizations, two courses of bilateral electroconvulsive therapy, and supportive psychotherapy with partial hospitalization. After the initiation of maintenance electroconvulsive therapy, this patient was able to tolerate residential placement and begin a work therapy program with only one instance of self-injurious behavior in the past 17 months.

Adult↗

Prasterone (DHEA) and mania.

OBJECTIVE: To inform clinicians and investigators of the potential for severe mania in conjunction with the use of prasterone (DHEA; dehydroepiandrosterone). CASE SUMMARY: A 31-year-old Hispanic man was admitted on a 72-hour observation period from a neighboring hospital after threatening to kill himself, family members, and a friend. A loaded rifle was found under his bed. The family confirmed that he had begun using DHEA several weeks prior to his mood and behavioral changes. He denied any past violence, but had once been given an unsubstantiated diagnosis of bipolar disorder. He used alcohol episodically, and had difficulties controlling his anger while intoxicated. Although he improved with valproate, his threats of homicide led to involuntary commitment. DISCUSSION: Several studies and case reports strongly suggest that anabolic steroids can induce significant psychiatric difficulties, including mania, impaired cognition, and overt psychosis. Although the Food and Drug Administration noted in 1985 that the efficacy and safety of DHEA were never confirmed, the agent continues to be sold over the counter. Several groups have used DHEA in the treatment of AIDS, memory loss, and depression, but reported no serious adverse events; however, recent studies indicate that severe psychiatric symptoms can develop in a subset of users. Although uncertain, potential risk factors include high doses of DHEA; history of mood disorder; concurrent use of alcohol, street drugs, or antidepressants; and cytochrome P450 polymorphisms. CONCLUSIONS: The use of DHEA in those under age 35 years may be especially risky, as endogenous DHEA concentrations peak at age 20-30 years. Those using or investigating DHEA should be cognizant of the potential for severe psychiatric complications.

Adjuvants, Immunologic↗

Lack of promotional effects of groundwater contaminant mixtures on the induction of preneoplastic foci in rat liver.

F344 rats were exposed to drinking water mixtures of seven of the most common groundwater contaminants associated with hazardous waste sites [arsenic, benzene, chloroform, chromium, lead, phenol, and trichloroethylene (TCE)] as the full mixture or submixtures of the organic and/or inorganic chemicals. The lowest concentrations (1x) of the individual chemicals were environmentally realistic and below what would be expected to induce significant short-term toxicity. This study was intended to determine if previously reported increases in localized hepatocellular proliferation in response to these chemicals might be correlated with increased risk for hepatocarcinogenesis. Rats were exposed via a drinking water solution to the full seven- chemical mixture (at 1x and 10x concentrations), submixtures of the organic or inorganic chemicals (at 10x concentrations), a mixture of TCE, lead, and chloroform (TLC submixture at 10x and 100x concentrations), or deionized water as a control. The rats were evaluated for promotion of placental glutathione-S-transferase (GST-P) positive preneoplastic liver cell foci after diethylnitrosamine (DEN) initiation and partial hepatectomy. Focus formation, cell proliferation, and apoptosis were evaluated after exposure to DEN or saline controls, the chemical mixtures or deionized water controls, or combinations of these treatments. The total number and area of GST-P positive foci in DEN-treated rats exposed to the full seven-chemical mixture was increased as compared with the DEN-water controls, but this was statistically significant only for total focus area in the 1x dose group. In DEN-treated rats, the inorganic or TLC submixtures resulted in a significant reduction in number and area of GST-P positive foci. Focus area also was decreased in the organic submixture-treated group, but not significantly. Hepatocellular proliferation was not significantly changed in the chemical mixture saline groups as compared with the mixture water controls. After DEN treatment, however, cell proliferation was significantly decreased after the 10x seven-chemical and organic mixture treatments and the 100x TLC mixture treatment. Different groups showed either increased or decreased apoptotic rates which did not correlate well with proliferation rates or focus formation. Mixtures of these seven chemicals, therefore, did not appear to act as promoters of hepatic foci at environmentally relevant concentrations, and some mixture combinations appeared to decrease promotional activity.

Animals↗

Bursal anti-steroidogenic peptide (BASP): modulation of mitogen-stimulated bursal-lymphocyte DNA synthesis.

The present study examined the effects of bursal anti-steroidogenic peptide (BASP) on mitogen-induced DNA synthesis in bursa-derived B-lymphocytes in short-term culture. Partially purified extracts of chicken bursa of Fabricius tissue, containing BASP, significantly (P < 0.05) reduced DNA synthesis in bursal-lymphocytes exposed to increasing concentrations of phorbol 12,13-dibutyrate (PDB). Following these initial observations, BASP, further purified from bursal extracts using sequential rpHPLC fractionation, was observed to reduce (P < 0.05) both B-lymphocyte PDB-stimulated DNA synthesis and ovarian granulosa cell progesterone biosynthesis with bioactivity observed at similar retention times in each assay, suggesting that each bioactivity may be due to the same or similar molecules. A similar BASP-enriched fraction was not effective in altering basal levels of DNA synthesis in chick embryonic kidney cells. Subsequently, BASP was further purified by several sequential chromatographic methods including: C-18 rpHPLC (preparative rpHPLC followed by a semi-preparative rpHPLC column), cation exchange chromatography, molecular sieve HPLC chromatography, and SDS-PAGE. Biologically active material was observed at approximately 29 or 34 kDa. Protein concentration was determined and bioactivity was evaluated. Anti-proliferative effects of this partially purified BASP on bursal-lymphocytes was observed at concentrations as low as 1.6 micrograms ml-1, with complete suppression of mitogen-stimulated DNA synthesis observed at approximately 25 micrograms ml-1. This partially purified BASP was also efficacious for attenuation of ovarian granulosa cell progesterone biosynthesis at concentrations as low as 0.4 microgram ml-1, with complete suppression of gonadotrophin-stimulated progesterone biosynthesis observed at approximately 0.8 microgram ml-1. While BASP is efficacious for attenuation of both granulosa cell steroidogenesis and bursal-lymphocyte proliferation, these data suggest that BASP is much more potent with regard to anti-steroidogenic activity.

B-Lymphocytes↗

Regulation of somatotroph differentiation and growth hormone (GH) secretion by corticosterone and GH-releasing hormone during embryonic development.

The role of extracellular factors in the regulation of anterior pituitary cell differentiation and GH secretion during embryonic development was investigated. Previously, we reported that somatotrophs become a significant population by embryonic day (e-) 16 of the chick and that corticosterone is the active compound responsible for the observed GH cell-differentiating activity of e-16 serum. More recently, the influence of hormone interactions on somatotroph differentiation and GH secretion during mid- to late embryogenesis was evaluated. Anterior pituitary cells from e-12, -14, and -17 chicks were cultured for 2, 3, and 6 days with corticosterone (10(-9) M) and GH-releasing hormone (GHRH; 10(-10)-10(-7) M) alone and in combination. Medium samples were analyzed for GH concentrations, and recovered cells were subjected to GH reverse hemolytic plaque assay for determination of somatotroph percentages and the relative amount of GH secretion from individual somatotrophs. GHRH significantly (P < 0.05) increased GH secretion from e-17, but not e-12 and e-14, pituitary cells during 2 and 3 days of culture. Corticosterone alone failed to increase GH secretion from e-12, -14, and -17 pituitary cells; however, corticosterone in combination with GHRH increased GH secretion from cells of all three ages. Culture with GHRH decreased percentages of e-17 GH-secreting cells in a concentration-dependent manner (from basal levels of 12.3 +/- 2.4% to 3.2 +/- 0.7% by 2 days), but did not affect percentages of e-12 and e-14 somatotrophs. Conversely, corticosterone increased percentages of e-12 and e-14 GH-secreting cells (by as much as 14- and 3-fold above basal levels, respectively), but did not alter the proportions of e-17 GH cells. Corticosterone in combination with GHRH was more effective than either hormone alone for increasing percentages of e-12 GH-secreting cells (from 9.6 +/- 0.8% with corticosterone to 15.9 +/- 1.5% with corticosterone plus GHRH), but this synergistic effect was not apparent until after 3 days of culture. Exposure to corticosterone in culture for 2, 3, and 6 days increased subsequent GH release from e-12 and e-14 pituitary cells during reverse hemolytic plaque assay. Combined treatment with corticosterone and GHRH further increased subsequent GH release from e-12 and e-14 cells. We conclude that glucocorticoids induce GH cell differentiation and that corticosterone and GHRH can interact at specific stages of embryonic development to regulate somatotroph differentiation and GH secretion.

Animals↗

Induction of somatotroph differentiation in vivo by corticosterone administration during chicken embryonic development.

Somatotroph differentiation in the embryonic pituitary of avian and mammalian species can be stimulated by glucocorticoids in vitro, and this effect can be augmented by concomitant treatment with growth hormone-releasing hormone (GHRH). Owing to its isolation from maternal influences, the chick embryo is a useful model for studying humoral regulation of pituitary cell differentiation. Somatotroph differentiation in chickens occurs between embryonic day (e-) 14 and e-16, and treatment of e-12 pituitary cells with e-16 serum or corticosterone induces growth hormone (GH) cell differentiation within 2 d in culture. The objective of the present study was to determine whether direct administration of embryonic serum and corticosterone to developing chick embryos was effective in vivo in inducing somatotroph differentiation prematurely. The albumen of fertile eggs was injected on e-11 with 300 approximately microL of 0.9% saline or 150 microL of serum from e-12 or e-16 chick embryos diluted 1:1 with saline. The embryos were allowed to develop until e-14, when pituitaries were dispersed and the resulting pituitary cells were subjected to reverse hemolytic plaque assays (RHPA) and immunocytochemistry to detect GH-secreting and GH-containing cells, respectively. Injection of e-16 serum increased (p < 0.01) GH-secreting and GH-containing cells to 11.5 +/- 1.0% and 1 7.4 +/- 3.3% of all pituitary cells, compared to 5.0 +/- 0.3% and 5.5 +/- 0.9% for saline-injected controls, respectively. Day 12 serum increased GH-containing cells to 9.8 +/- 0.9%, without changing percentages of GH-secreting cells. In experiment 2, saline, e-16 serum, and corticosterone were injected on e-11, and pituitary cells were subjected to GH RHPA on e-14. GH secretors were increased by e-16 serum and corticosterone. In experiment 3, we tested whether GHRH would magnify the effect of corticosterone, as we had seen in extended 6-d cultures previously. Saline, corticosterone, and corticosterone plus GHRH were injected on e-11, and pituitary cells were subjected to GH RHPA on e-18. Treatment with corticosterone alone and combined with GHRH increased the percentage of GH-secreting cells. However, combined treatment with corticosterone and GHRH was not more effective than corticosterone alone. The present findings demonstrate that glucocorticoid administration can stimulate somatotroph differentiation in living vertebrate embryos isolated from maternal interactions.

Animals↗

Expression of chicken thyroid-stimulating hormone beta-subunit messenger ribonucleic acid during embryonic and neonatal development.

The importance of thyroid hormone from embryonic through neonatal life has been documented in both avian and mammalian species. However, the regulation of thyroid hormone production during this period is not completely understood. The objective of this study was to characterize expression of chicken TSHbeta messenger RNA (mRNA) compared with that of thyroid hormones and GH in embryonic and neonatal chickens. Total pituitary RNA was extracted on embryonic days (e-) 11, 13, 15, 17, and 19 and neonatal days (d-) 1, 3, 6, 9, and 12 and subjected to ribonuclease protection assays (RPA) for chicken TSHbeta mRNA. TSHbeta mRNA levels increased through e-19, with e-19 levels being greater than those at all other embryonic ages (P < 0.05). Levels decreased markedly on d-1, then slowly increased to d-6 and stayed elevated through d-12. RIAs were performed for T4, T3, and GH at the same ages. Serum T4 levels increased slowly from less than 1.0 ng/ml on e-11 to a peak of 6.6 ng/ml on d-1 (P < 0.05). After the peak on d-1, posthatch T4 levels stabilized between 3.5-4.5 ng/ml through d-12 (P < 0.05). T3 concentrations were less than 0.25 ng/ml on e-11, increased dramatically between e-19 and d-1 (P < 0.05), and remained high throughout the rest of the experiment, with a concentration of 3.25 ng/ml on d-6 (P < 0.05). GH levels for e-11 through e-17 were below the sensitivity of the GH RIA. On e-19, the GH level was 3 ng/ml and continued to increase through d-12 to a level of 130 ng/ml. As thyroid hormone levels were preceded by maximal TSHbeta mRNA levels on e-19, we next determined whether TSHbeta gene expression on e-19 was under TRH and T3 regulation. E-19 anterior pituitary cells were cultured in serum-free medium with either TRH (10[-8]) or T3 (10[-8]) for 20-24 h. Treatment with T3 significantly decreased levels of TSHbeta mRNA (P < 0.05). However, TRH did not produce a significant increase in TSHbeta mRNA, although TRH did increase TSHbeta mRNA by 60%, on the average, in this study. Therefore, these results indicate that an increase in pituitary TSH production probably regulates thyroid hormone levels during late embryonic development and that negative feedback inhibition of TSH production by thyroid hormones also exists at this critical developmental stage.

Animals↗

Differential responsiveness of somatotrophs to growth hormone-releasing hormone and thyrotropin-releasing hormone during chicken embryonic development.

This study was designed to evaluate responsiveness and sensitivity of pituitaries from chickens to growth hormone (GH) secretagogues during late embryonic development. Anterior pituitary cells from 16-, 18- and 20-day-old chicken embryos were subjected to reverse hemolytic plaque assays (RHPAs) for GH in the presence of GH-releasing hormone (GHRH) and thyrotropin-releasing hormone (TRH). The proportion of somatotrophs detected increased between embryonic days 16 and 20, from 16 to 19.5% of all pituitary cells. Sensitivity to GHRH and TRH was similar and increased between embryonic days 16 and 20. On embryonic day 16, about 50% of somatotrophs that were not detected under basal conditions released GH in the presence of GHRH at 2 and 6 h. In contrast, only 15 and 30% of day 16 somatotrophs released GH by 2 and 6 h, respectively, following exposure to TRH. Thus, at least one of five somatotrophs responded to GHRH but not to TRH. By embryonic day 20, the proportions of somatotrophs that responded to GHRH and TRH were approximately equal at about 40%. These results provide additional evidence that GHRH and TRH may be involved in hypothalamic regulation of GH secretion during chicken embryonic development. Furthermore, it appears that full differentiation of functional chicken somatotrophs does not occur abruptly but rather gradually between embryonic days 16 and 20, during which a subpopulation of GH cells undergoes changes in sensitivity and responsiveness to TRH.

Animals↗

Identification of the blood-borne somatotroph-differentiating factor during chicken embryonic development.

Somatotrophs become a significant population by day 16 of chicken embryonic development. We have previously demonstrated that an earlier induction of GH cell differentiation is possible with the addition of day 16 embryonic serum to cultures of day 12 pituitary cells, an age when somatotrophs are rare. The present study was designed to identify the blood-borne signal(s) responsible for the serum activity, using reverse hemolytic plaque assays to identify individual GH-secreting cells. The activity was found to be a heat-stable, ether-soluble compound(s) that is bound or inhibited by a trypsin-sensitive protein. The extent of GH cell differentiation was greater (P < 0.05; n = 3) in response to the ether phases of heated day 16 (14.1 +/- 0.4% of all cells) and day 12 sera (9.3 +/- 0.4%) than with untreated serum from days 16 and 12 (6.1 +/- 0.4% and 0.82 +/- 0.4%, respectively). Furthermore, ether-extracted day 16 serum was more effective than ether-extracted day 12 serum, which was also different from basal (0.85 +/- 0.4%; P < 0.05). Based on this biochemical profile, the abilities of various steroids to stimulate differentiation were tested. Three steroids were found to stimulate somatotroph differentiation in vitro: 17beta-estradiol, corticosterone, and progesterone. However, the estradiol receptor antagonist, tamoxifen, while abolishing the effect of estradiol, had no effect on the induction of differentiation by day 16 serum. In contrast, RU486, a specific glucocorticoid receptor antagonist in chickens, blocked the stimulatory effects of corticosterone, progesterone, and day 16 serum on somatotroph differentiation. We next tested whether the active compound in day 16 embryonic serum was corticosterone, the predominant glucocorticoid in chickens. Incubation of day 16 serum with corticosterone antiserum, but not control antiserum, suppressed day 16 serum-induced GH cell differentiation. Therefore, we conclude that corticosterone is the blood-borne signal capable of stimulating somatotroph differentiation in vitro. The present findings together with previous reports indicate that somatotroph differentiation during embryonic development may result from an increase in circulating glucocorticoid concentrations.

Animals↗

Persistent cloaca and caudal spinal agenesis in calves: three cases.

Three newborn calves were affected by caudal spinal dysgenesis or agenesis (coccygeal vertebra) and persistent cloaca. The cloacas were lined by a mixture of transitional and colonic epithelium. The vertebral column of one calf was internalized into the cloaca. The association of persistent cloaca and caudal spinal anomalies is thought to be related to cell loss in the caudal cell mass, which affects caudal spinal column formation and cleavage of the cloaca by the urorectal septum. This association is well documented in humans and has been reported in Manx cats. By extrapolation, it appears likely to exist also in neonatal calves. Identification of cloacal lesions in neonatal animals should be cause for careful examination of the vertebral column because many of the associated spinal lesions are occult.

Animals↗